|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics. CA Cancer J Clin. 56:106–130. 2006.
|
|
2
|
Kirby R: Management of clinically
localized prostate cancer by radical prostatectomy followed by
watchful waiting. Nat Clin Pract Urol. 2:298–303. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bedford M and van Helden PD:
Hypomethylation of DNA in pathological conditions of the human
prostate. Cancer Res. 47:5274–5276. 1987.PubMed/NCBI
|
|
4
|
Nakayama M, Bennett CJ, Hicks JL, Epstein
JI, Platz EA, Nelson WG and De Marzo AM: Hypermethylation of the
human glutathione S-transferase-π gene (GSTP1) CpG island is
present in a subset of proliferative inflammatory atrophy lesions
but not in normal or hyperplastic epithelium of the prostate: a
detailed study using laser-capture microdissection. Am J Pathol.
163:923–933. 2003.
|
|
5
|
Brooks JD, Weinstein M, Lin X, Sun Y, Pin
SS, Bova GS, Epstein JI, Isaacs WB and Nelson WG: CG island
methylation changes near the GSTP1 gene in prostatic
intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev.
7:531–536. 1998.PubMed/NCBI
|
|
6
|
Nelson CP, Kidd LC, Sauvageot J, Isaacs
WB, De Marzo AM, Groopman JD, Nelson WG and Kensler TW: Protection
against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine
cytotoxicity and DNA adduct formation in human prostate by
glutathione S-transferase P1. Cancer Res. 61:103–109. 2001.
|
|
7
|
Lin X, Tascilar M, Lee WH, Vles WJ, Lee
BH, Veeraswamy R, Asgari K, Freije D, et al: GSTP1 CpG island
hypermethylation is responsible for the absence of GSTP1 expression
in human prostate cancer cells. Am J Pathol. 159:1815–1826. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Henderson CJ, Smith AG, Ure J, Brown K,
Bacon EJ and Wolf CR: Increased skin tumorigenesis in mice lacking
π-class glutathione S-transferases. Proc Natl Acad Sci USA.
95:5275–5280. 1998.
|
|
9
|
De Marzo AM, Marchi VL, Epstein JI and
Nelson WG: Proliferative inflammatory atrophy of the prostate:
implications for prostatic carcinogenesis. Am J Pathol.
155:1985–1992. 1999.PubMed/NCBI
|
|
10
|
Kano M, Bell DW, Haber DA and Li E: DNA
methyltransferases Dnmt3a and Dnmt3b are essential for de novo
methylation and mammalian development. Cell. 99:247–257. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu R, Wang X, Chen ZF, Sun DF, Tian XQ, et
al: Inhibition of the extracellular signal-regulated
kinase/mitogen-activated protein kinase pathway decreases DNA
methylation in colon cancer cells. J Biol Chem. 282:12249–12259.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bai T, Tanaka T, Yukawa K and Umesaki N: A
novel mechanism for acquired cisplatin-resistance: Suppressed
translation of death-associated protein kinase mRNA is insensitive
to 5-aza-2′-deoxycitidine and trichostatin in cisplatin-resistant
cervical squamous cancer cells. Int J Oncol. 28:497–508.
2006.PubMed/NCBI
|
|
13
|
Gravina GL, Festuccia C, Marampon F, Popov
VM, Pestell RG, Zani BM and Tombolini V: Biological Rationale for
the use of DNA methyltransferase inhibitors as new strategy for
modulation of tumor response to chemotherapy and radiation. Mol
Cancer. 9:305–321. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zorn CS, Wojno KJ, McCabe MT, Kuefer R,
Gschwend JE, et al: 5-aza-2′-deoxycytidine delays
androgen-independent disease and improves survival in the
transgenic adenocarcinoma of the mouse prostate mouse model of
prostate cancer. Clin Cancer Res. 13:2136–2143. 2007.
|
|
15
|
Morey Kinney SR, Smiraglia DJ, James SR,
Moser MT, Foster BA and Karpf AR: Stage-specific alterations of DNA
methyltransferase expression, DNA hypermethylation, and DNA
hypomethylation during prostate cancer progression in the
transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res.
6:1365–1374. 2008.
|
|
16
|
Stewart DJ, Issa JP, Kurzrock R, Nunez MI,
Jelinek J, et al: Decitabine effect on tumor global DNA methylation
and other parameters in a phase I trial in refractory solid tumors
and lymphomas. Clin Cancer Res. 15:3881–3888. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iwata H, Sato H, Suzuki R, Yamada R,
Ichinomiya S, Yanagihara M, et al: A demethylating agent enhances
chemosensitivity to vinblastine in a xenograft model of renal cell
carcinoma. Int J Oncol. 38:1653–1661. 2011.PubMed/NCBI
|
|
18
|
Perry AS, Foley R, Woodson K and Lawler M:
The emerging roles of DNA methylation in the clinical management of
prostate cancer. Endocr Relat Cancer. 13:357–377. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pulukuri SM and Rao JS: Activation of
p53/p21Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell
proliferation, induces pro-apoptotic genes and mitogen-activated
protein kinases in human prostate cancer cells. Int J Oncol.
26:863–871. 2005.
|
|
20
|
Festuccia C, Gravina GL, D’Alessandro AM,
Millimaggi D, Di Rocco C, Dolo V, et al: Downmodulation of dimethyl
transferase activity enhances tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis in prostate cancer
cells. Int J Oncol. 33:381–388. 2008.
|
|
21
|
Festuccia C, Gravina GL, D’Alessandro AM,
Muzi P, Millimaggi D, Dolo V, et al: Azacitidine improves antitumor
effects of docetaxel and cisplatin in aggressive prostate cancer
models. Endocr Relat Cancer. 16:401–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Groeningen CJ, Leyva A, O’Brien AM,
Gall HE and Pinedo HM: Phase I and pharmacokinetic study of
5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res.
46:4831–4836. 1986.
|
|
23
|
Thibault A, Figg WD, Bergan RC, Lush RM,
Myers CE, et al: A phase II study of 5-aza-2′deoxycytidine
(decitabine) in hormone independent metastatic (D2) prostate
cancer. Tumori. 84:87–89. 1998.
|
|
24
|
Kastl L, Brown I and Schofield AC: Altered
DNA methylation is associated with docetaxel resistance in human
breast cancer cells. Int J Oncol. 36:1235–1241. 2010.PubMed/NCBI
|
|
25
|
Gravina GL, Marampon F, Piccolella M,
Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG,
Tombolini V, Jannini EA and Festuccia C: Hormonal therapy promotes
hormone-resistant phenotype by increasing DNMT activity and
expression in prostate cancer models. Endocrinology. 152:4550–4561.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gravina GL, Festuccia C, Millimaggi D,
Dolo V, Tombolini V, de Vito M, Vicentini C and Bologna M: Chronic
azacitidine treatment results in differentiating effects,
sensitizes against bicalutamide in androgen-independent prostate
cancer cells. Prostate. 68:793–801. 2008. View Article : Google Scholar
|
|
27
|
Gravina GL, Marampon F, Di Staso M,
Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V and
Festuccia C: 5-Azacitidine restores and amplifies the bicalutamide
response on preclinical models of androgen receptor expressing or
deficient prostate tumors. Prostate. 70:1166–1178. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sinisi AA, Chieffi P, Pasquali D,
Kisslinger A, Staibano S, Bellastella A and Tramontano D: EPN: a
novel epithelial cell line derived from human prostate tissue. In
Vitro Cell Dev Biol Anim. 23:165–172. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tepper CG, Boucher DL, Ryan PE, et al:
Characterization of a novel androgen receptor mutation in a
relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res.
62:6606–6612. 2002.PubMed/NCBI
|
|
30
|
Craft N, Shostak Y, Carey M, et al: A
mechanism for hormone-independent prostate cancer through
modulation of androgen receptor signaling by the HER-2/neu tyrosine
kinase. Nat Med. 5:280–288. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Korenchuk S, Lehr JE, MClean L, Lee YG,
Whitney S, Vessella R, Lin DL and Pienta KJ: VCaP, a cell-based
model system of human prostate cancer. In Vivo. 15:163–168.
2001.PubMed/NCBI
|
|
32
|
Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn
E, Patel AH, Morris MD and Keller ET: Bone metastatic
LNCaP-derivative C4–2B prostate cancer cell line mineralizes in
vitro. Prostate. 47:212–218. 2001.
|
|
33
|
Pettaway CA, Pathak S, Greene G, Ramirez
E, Wilson MR, Killion JJ and Fidler IJ: Selection of highly
metastatic variants of different human prostatic carcinomas using
orthotopic implantation in nude mice. Clin Cancer Res. 2:1627–1636.
1996.PubMed/NCBI
|
|
34
|
Festuccia C, Vincentini C, di Pasquale AB,
Aceto G, Zazzeroni F, Miano L and Bologna M: Plasminogen activator
activities in short-term tissue cultures of benign prostatic
hyperplasia and prostatic carcinoma. Oncol Res. 7:131–138.
1995.PubMed/NCBI
|
|
35
|
Festuccia C, Angelucci A, Gravina GL, Muzi
P, Miano R, Vicentini C and Bologna M: Epithelial and prostatic
marker expression in short-term primary cultures of human prostate
tissue samples. Int J Oncol. 26:1353–1362. 2005.PubMed/NCBI
|
|
36
|
Gravina GL, Biordi L, Martella F, Flati V,
Ricevuto E, Ficorella C, Tombolini V and Festuccia C: Epigenetic
modulation of PTEN expression during antiandrogenic therapies in
human prostate cancer. Int J Oncol. 35:1133–1139. 2009.PubMed/NCBI
|
|
37
|
Kaminskas E, Farrell A, Abraham S, Baird
A, Hsieh LS, Lee SL, Leighton JK, et al: Approval summary:
azacitidine for treatment of myelodysplastic syndrome subtypes.
Clin Cancer Res. 11:3604–3608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kantarjian H, Issa JP, Rosenfeld CS,
Bennett JM, Albitar M, DiPersio J, Klimek V, et al: Decitabine
improves patient outcomes in myelodysplastic syndromes: results of
a phase III randomized study. Cancer. 106:1794–1803. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chiam K, Centenera MM, Butler LM, Tilley
WD and Bianco-Miotto T: GSTP1 DNA methylation and expression status
is indicative of 5-aza-2′-deoxycytidine efficacy in human prostate
cancer cells. PLoS One. 6:e256342011.PubMed/NCBI
|
|
40
|
Mulder TP, Peters WH, Wobbes T, Witteman
BJ and Jansen JB: Measurement of glutathione S-transferase P1-1 in
plasma: pitfalls and significance of screening and follow-up of
patients with gastrointestinal carcinoma. Cancer. 80:873–880. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oude Ophuis MB, Mulder TP, Peters WH and
Manni JJ: Plasma glutathione S-transferase P1-1 levels in patients
with head and neck squamous cell carcinoma. Cancer. 82:2434–2438.
1998.
|
|
42
|
Prior C, Guillen-Grima F, Robles JE,
Rosell D, Fernandez-Montero JM, Agirre X, et al: Use of a
combination of biomarkers in serum and urine to improve detection
of prostate cancer. World J Urol. 28:681–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Patra SK, Patra A, Zhao H and Dahiya R:
DNA methyltransferase and demethylase in human prostate cancer. Mol
Carcinog. 33:163–171. 2002. View
Article : Google Scholar : PubMed/NCBI
|
